[go: up one dir, main page]

NO2013016I2 - Okriplasmin - Google Patents

Okriplasmin

Info

Publication number
NO2013016I2
NO2013016I2 NO2013016C NO2013016C NO2013016I2 NO 2013016 I2 NO2013016 I2 NO 2013016I2 NO 2013016 C NO2013016 C NO 2013016C NO 2013016 C NO2013016 C NO 2013016C NO 2013016 I2 NO2013016 I2 NO 2013016I2
Authority
NO
Norway
Prior art keywords
eye
reduce
vitreous
plasmin
disorder
Prior art date
Application number
NO2013016C
Other languages
English (en)
Other versions
NO2013016I1 (no
Original Assignee
Thrombogenics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9949140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2013016(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Thrombogenics Nv filed Critical Thrombogenics Nv
Publication of NO2013016I1 publication Critical patent/NO2013016I1/no
Publication of NO2013016I2 publication Critical patent/NO2013016I2/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01023—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24007—Interstitial collagenase (3.4.24.7), i.e. matrix metalloprotease 1 or MMP1
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/02—Carbon-oxygen lyases (4.2) acting on polysaccharides (4.2.2)
    • C12Y402/02004—Chondroitin ABC lyase (4.2.2.4), i.e. chondroitinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/02—Carbon-oxygen lyases (4.2) acting on polysaccharides (4.2.2)
    • C12Y402/02005—Chondroitin AC lyase (4.2.2.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/02—Carbon-oxygen lyases (4.2) acting on polysaccharides (4.2.2)
    • C12Y402/02019—Chondroitin B lyase (4.2.2.19)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Inorganic Insulating Materials (AREA)
NO2013016C 2002-12-06 2013-11-19 Okriplasmin NO2013016I2 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0228409.9A GB0228409D0 (en) 2002-12-06 2002-12-06 Pharmacological vitreolysis
PCT/US2003/038714 WO2004052228A2 (en) 2002-12-06 2003-12-05 Pharmacological vitreolysis

Publications (2)

Publication Number Publication Date
NO2013016I1 NO2013016I1 (no) 2013-11-19
NO2013016I2 true NO2013016I2 (no) 2017-06-28

Family

ID=9949140

Family Applications (4)

Application Number Title Priority Date Filing Date
NO20052988A NO333837B1 (no) 2002-12-06 2005-06-17 Anvendelse av en sammensetning som omfatter et trunkert plasminprotein for fremstilling av et medikament for behandling av en lidelse i et øye samt sammensetning og sett.
NO20121170A NO20121170A1 (no) 2002-12-06 2012-10-12 Farmakologisk vitreolyse
NO20121169A NO343759B1 (no) 2002-12-06 2012-10-12 Første preparat omfattende et trunkert plasminprotein (TPCD) omfattende en katalytisk domene av plasmin og et andre preparat omfattende et ytterligere middel for anvendelse, samt sett.
NO2013016C NO2013016I2 (no) 2002-12-06 2013-11-19 Okriplasmin

Family Applications Before (3)

Application Number Title Priority Date Filing Date
NO20052988A NO333837B1 (no) 2002-12-06 2005-06-17 Anvendelse av en sammensetning som omfatter et trunkert plasminprotein for fremstilling av et medikament for behandling av en lidelse i et øye samt sammensetning og sett.
NO20121170A NO20121170A1 (no) 2002-12-06 2012-10-12 Farmakologisk vitreolyse
NO20121169A NO343759B1 (no) 2002-12-06 2012-10-12 Første preparat omfattende et trunkert plasminprotein (TPCD) omfattende en katalytisk domene av plasmin og et andre preparat omfattende et ytterligere middel for anvendelse, samt sett.

Country Status (24)

Country Link
US (11) US7547435B2 (no)
EP (3) EP2327415B1 (no)
JP (4) JP5426063B2 (no)
CN (1) CN100577202C (no)
AT (1) ATE534400T1 (no)
AU (1) AU2003300821C1 (no)
BE (1) BE2013C055I2 (no)
BR (2) BRPI0310144A8 (no)
CA (1) CA2508606C (no)
CY (2) CY1112561T1 (no)
DK (1) DK1581254T3 (no)
ES (2) ES2731625T3 (no)
FR (1) FR13C0052I2 (no)
GB (1) GB0228409D0 (no)
HU (1) HUS1300040I1 (no)
IL (3) IL169008A (no)
LU (1) LU92273I2 (no)
MX (1) MXPA05006038A (no)
NO (4) NO333837B1 (no)
NZ (1) NZ541075A (no)
PT (2) PT1581254E (no)
SI (1) SI1581254T1 (no)
WO (1) WO2004052228A2 (no)
ZA (1) ZA200505193B (no)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7152975B2 (en) * 2000-11-10 2006-12-26 Cooper Vision, Inc. Junctionless ophthalmic lenses and methods for making same
GB0228409D0 (en) 2002-12-06 2003-01-08 Thromb X Nv Pharmacological vitreolysis
ES2349555T3 (es) 2004-04-22 2011-01-05 Talecris Biotherapeutics, Inc. Plasmina modificada recombinántemente.
JP4796787B2 (ja) 2005-04-28 2011-10-19 富士フイルム株式会社 ラビリンチュラ類への遺伝子導入法
US20060257391A1 (en) * 2005-05-11 2006-11-16 Bausch & Lomb Incorporated Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions
US20080248021A1 (en) * 2005-06-30 2008-10-09 Ista Pharmaceuticals, Inc. Use of Hyaluronidase in Combination with Plasmin for the Induction of Posterior Vitreous Detachment
WO2007047874A2 (en) * 2005-10-20 2007-04-26 Talecris Biotherapeutics, Inc. Recombinantly modified plasmin
US20070134230A1 (en) * 2005-12-13 2007-06-14 Jani Dharmendra M Method for prolonging activity of autodegradable enzymes
US20070134231A1 (en) * 2005-12-13 2007-06-14 Jani Dharmendra M Method for prolonging activity of autodegradable enzymes and compositions thereof
US20070196350A1 (en) * 2006-02-22 2007-08-23 Bartels Stephen P Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment
US20070212358A1 (en) * 2006-03-10 2007-09-13 Bartels Stephen P Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment
CA2651194A1 (en) * 2006-05-04 2007-11-15 Fondation Ophthalmologique Aldolphe De Rothschild Methods for treating neovascular diseases
CA2707266C (en) * 2007-11-29 2013-12-31 Talecris Biotherapeutics, Inc. Recombinantly modified plasmin
US20110142819A1 (en) * 2008-01-22 2011-06-16 Omnio Healer Ab Method of improving would healing
US20110097421A1 (en) * 2008-03-31 2011-04-28 Bruno Gogly Method for the Cosmetic Treatment of Skin Ageing
NZ589557A (en) 2008-06-04 2012-08-31 Talecris Biotherapeutics Inc Immobilised streptokinase, method and kit for preparing plasmin
HUE025670T2 (en) 2009-03-03 2016-04-28 Grifols Therapeutics Inc A method for producing plasminogen
US8858924B2 (en) * 2009-03-26 2014-10-14 Warsaw Orthopedic, Inc. Compositions and methods for treatment of hemorrhage
EP2451835A1 (en) 2009-07-10 2012-05-16 ThromboGenics N.V. Variants of plasminogen and plasmin
EP2480249B1 (en) 2009-08-28 2015-01-28 ThromboGenics N.V. Plasmin for the treatment of filtration failure after trabeculectomy
US20110135626A1 (en) * 2009-12-08 2011-06-09 Alcon Research, Ltd. Localized Chemical Lysis of Ocular Tissue
RU2435553C1 (ru) * 2010-03-10 2011-12-10 Арсений Александрович Кожухов Способ лечения центральных субретинальных кровоизлияний
BR112013017172A2 (pt) 2011-01-05 2016-10-11 Thrombogenics Nv variantes de plasminogênio e plasmina
EP2720691A1 (en) * 2011-06-17 2014-04-23 Allergan, Inc. D -serine for the treatment of visual system disorders
JP6000353B2 (ja) 2011-08-12 2016-09-28 スロンボジェニックス・ナムローゼ・フェンノートシャップＴｈｒｏｍｂｏＧｅｎｉｃｓ ＮＶ プラスミノーゲンおよびプラスミンの変異体
RU2484795C2 (ru) * 2011-08-18 2013-06-20 Федеральное государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова Федерального агентства по высокотехнологичной медицинской помощи" Способ индукции задней отслойки стекловидного тела с помощью миниплазмина
PL2785739T3 (pl) 2011-12-01 2017-10-31 Thrombogenics Nv Poprawa wyniku trabekulektomii
CN103205410B (zh) * 2012-01-13 2018-03-06 蔺莹莹 重组微纤维蛋白溶酶及其制备方法和应用
KR20150005631A (ko) 2012-04-24 2015-01-14 쓰롬보제닉스 엔.브이. 항-pdgf-c 항체
WO2014160281A2 (en) * 2013-03-14 2014-10-02 Wayne State University Method of enhancing delivery of therapeutic compounds to the eye
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US9459201B2 (en) 2014-09-29 2016-10-04 Zyomed Corp. Systems and methods for noninvasive blood glucose and other analyte detection and measurement using collision computing
FR3034992A1 (fr) 2015-04-15 2016-10-21 Arcadophta Milieu plasmatique ex vivo autologue riche en plasmine et procede d'obtention
TWI653981B (zh) 2015-12-18 2019-03-21 深圳瑞健生命科學硏究院有限公司 Use of plasminogen for the preparation of a medicament for preventing or treating a condition associated with diabetic nerve injury
JP6682008B2 (ja) 2015-12-18 2020-04-15 タレンゲン インターナショナル リミテッドＴａｌｅｎｇｅｎ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｉｍｉｔｅｄ 糖尿病性腎症を予防及び治療するための方法
CA3008691A1 (en) * 2015-12-18 2017-06-22 Talengen International Limited Method for preventing or treating diabetic retinopathy
JP7088454B2 (ja) 2015-12-30 2022-06-21 コディアック サイエンシーズ インコーポレイテッド 抗体および抗体複合体
RU2619991C1 (ru) * 2016-02-18 2017-05-22 Павел Владимирович Лыскин Способ лечения витреомакулярного тракционного синдрома
CN108779173A (zh) 2016-03-10 2018-11-09 思罗姆博基因股份有限公司 通过拮抗胎盘生长因子抑制眼后部纤维化
US9554738B1 (en) 2016-03-30 2017-01-31 Zyomed Corp. Spectroscopic tomography systems and methods for noninvasive detection and measurement of analytes using collision computing
US11129880B2 (en) 2016-12-15 2021-09-28 Talengen International Limited Method for promoting insulin secretion
CN110506105B (zh) 2017-03-28 2023-03-24 森永乳业株式会社 新型双歧杆菌属细菌
RU2674926C1 (ru) * 2018-02-01 2018-12-13 Федеральное государственное автономное учреждение "Национальный медицинский исследовательский центр "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации (ФГАУ "НМИЦ "МНТК "Микрохирургия глаза" им. акад. С.Н. Способ оценки эффективности витреолизиса помутнений стекловидного тела
JP2021514656A (ja) 2018-03-02 2021-06-17 コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． Ｉｌ−６抗体ならびにその融合構築物およびコンジュゲート
CN110361242B (zh) * 2019-08-14 2022-01-18 武汉赛维尔生物科技有限公司 一种用于眼球组织的固定液以及眼球组织制片的预处理方法
EP4041312A4 (en) 2019-10-10 2023-12-20 Kodiak Sciences Inc. METHOD FOR TREATING AN EYE DISORDER
CN116716251A (zh) * 2023-06-20 2023-09-08 中国医学科学院北京协和医院 一种玻璃体样本的单细胞处理方法及其应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US658972A (en) * 1900-04-09 1900-10-02 Interchangeable Brake Beam Company Brake-beam.
US2624691A (en) * 1946-04-22 1953-01-06 Parke Davis & Co Fibrinolysin derived from blood and methods of obtaining the same
DK98833C (da) 1961-04-25 1964-05-25 Novo Terapeutisk Labor As Fremgangsmåde til stabilisering af terapeutisk anvendelige plasminopløsninger.
US3234106A (en) * 1962-12-03 1966-02-08 Cutter Lab Soluble, purified profibrinolysin and fibrinolysin and method of producing same
US3950513A (en) * 1965-12-03 1976-04-13 Novo Terapeutisk Laboratorium A/S Process of stabilizing therapeutically useful plasmin solutions
IT1194135B (it) * 1981-01-05 1988-09-14 Novo Industri As Composizioni di plasmina stabilizzata e metodo per la loro preparazione
GB8504025D0 (en) 1985-02-16 1985-03-20 Biopharm Ltd Hyaluronidase
US4774087A (en) 1987-08-14 1988-09-27 Northwestern University Micro-size fibrinolytic plasmin
US5288485A (en) * 1989-08-31 1994-02-22 Kao Corporation Vasodilating agent
ZA912770B (en) 1990-04-16 1992-01-29 Bethesda Eye Inst Enzymatic disinsertion of vitreous body
US5288489A (en) * 1991-08-28 1994-02-22 Orion Therapeutic Systems, Inc. Fibrinolysis and fibrinogenolysis treatment
AU4661493A (en) * 1992-07-01 1994-01-31 Beth Israel Hospital Boston Enhancement of thrombolytic therapy with deglycosylated plasminogen
US5304118A (en) * 1992-12-16 1994-04-19 Trese Michael T Method for performing a vitrectomy on an eye
US5866120A (en) 1995-11-22 1999-02-02 Advanced Corneal Systems, Inc. Method for accelerating clearance of hemorrhagic blood from the vitreous humor with hyaluronidase
US6610292B2 (en) 1995-11-22 2003-08-26 Ista Pharmaceuticals, Inc. Use of hyaluronidase in the manufacture of an ophthalmic preparation for liquefying vitreous humor in the treatment of eye disorders
US5973779A (en) 1996-03-29 1999-10-26 Ansari; Rafat R. Fiber-optic imaging probe
US6207066B1 (en) * 1996-07-23 2001-03-27 Nuvue Technologies, L.L.C. Method for purification of a blood component
US6051698A (en) * 1997-06-06 2000-04-18 Janjic; Nebojsa Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US5722428A (en) * 1996-10-29 1998-03-03 Washington University Method for producing a posterior vitreous detachment
US6596725B2 (en) * 1997-02-10 2003-07-22 Inspire Pharmaceuticals, Inc. Use of certain dinucleotides to stimulate removal of fluid in retinal detachment and retinal edema
CN1257430A (zh) 1997-05-22 2000-06-21 先进角膜系统公司 透明质酸酶在制备用于治疗眼科疾病中液化玻璃体液的眼用制剂中的应用
ATE294865T1 (de) 1998-02-04 2005-05-15 Thromb X N V Identifizierung, produktion und verwendung von staphylokinase derivaten mit reduzierter immunogenizität und/oder reduzierter 'clearance'
US6378526B1 (en) 1998-08-03 2002-04-30 Insite Vision, Incorporated Methods of ophthalmic administration
US6462071B1 (en) 2000-03-02 2002-10-08 Vitreo-Retinal Technologies, Inc. Agents for intravitreal administration to treat or prevent disorders of the eye
US6585972B2 (en) * 1999-03-09 2003-07-01 Gholam A. Peyman Process for crosslinking of collagen in the vitreous of the eye and inducing separation of the posterior hyaloid from the retina
US6899877B2 (en) * 1999-03-09 2005-05-31 Minu, L.L.C. Process for generating plasmin in the vitreous of the eye and inducing separation of the posterior hyaloid from the retina
US6733750B1 (en) * 1999-03-09 2004-05-11 Minu, L.L.C. Process and composition for inducing posterior vitreous detachment
US20040081643A1 (en) * 1999-03-09 2004-04-29 Peyman Gholam A. Process for inhibiting vascular proliferation in the eye
EP1229116A4 (en) 1999-11-10 2003-01-22 Ct For Advanced Science & Tech METHOD FOR PRODUCING A CELL FACTION CONTAINING HEMANGIOBLASTES
US6964764B2 (en) * 1999-11-13 2005-11-15 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
US6355243B1 (en) * 1999-11-13 2002-03-12 Bayer Corporation Method of thrombolysis by local delivery of active plasmin
ES2260234T3 (es) * 2000-05-12 2006-11-01 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Utilizacion de inhibidores del factor de crecimiento placentario para el tratamiento de la angiogenesis patologica, de la arteriogenesis patologica, de la inflamacion, de la formacion tumoral y/o de la perdida vascular.
US7122181B2 (en) 2000-12-19 2006-10-17 Research Development Foundation Lentiviral vector-mediated gene transfer and uses thereof
ES2296705T3 (es) 2000-12-21 2008-05-01 Thrombogenics N.V. Vector de expresion de levadura y metodo de produccion de una proteina recombinada por la expresion de una celula de levadura.
US20020139378A1 (en) * 2001-03-28 2002-10-03 Trese Michael T. Method for creating a separation of posterior cortical vitreous from the retina of the eye
FI20011132A0 (fi) 2001-05-30 2001-05-30 Innovationsagentur Markkeri hematopoieettisten kantasolujen tunnistamiseen
US7776026B2 (en) * 2002-02-06 2010-08-17 Nuvue Technologies, Inc. Method for vitreous liquefaction
US6787135B2 (en) * 2002-03-13 2004-09-07 William Beaumont Hospital Modification of vitreal matrix metalloproteinase activity
WO2004045558A2 (en) * 2002-11-18 2004-06-03 President And Fellows Of Harvard College Compositions and methods for treating thrombotic disorders
GB0228409D0 (en) 2002-12-06 2003-01-08 Thromb X Nv Pharmacological vitreolysis
US20060257391A1 (en) 2005-05-11 2006-11-16 Bausch & Lomb Incorporated Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions
US20070212358A1 (en) * 2006-03-10 2007-09-13 Bartels Stephen P Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment

Also Published As

Publication number Publication date
JP5426063B2 (ja) 2014-02-26
NO2013016I1 (no) 2013-11-19
JP2006518708A (ja) 2006-08-17
JP2013241448A (ja) 2013-12-05
EP2327416B1 (en) 2019-05-01
US7914783B2 (en) 2011-03-29
EP1581254A2 (en) 2005-10-05
JP2015131842A (ja) 2015-07-23
FR13C0052I1 (no) 2013-04-10
FR13C0052I2 (fr) 2014-11-21
NZ541075A (en) 2008-02-29
CN1738641A (zh) 2006-02-22
DK1581254T3 (da) 2012-02-27
US7803368B2 (en) 2010-09-28
US20130302304A1 (en) 2013-11-14
CY1112561T1 (el) 2015-11-04
WO2004052228A2 (en) 2004-06-24
US8460655B2 (en) 2013-06-11
EP1581254A4 (en) 2007-03-28
BE2013C055I2 (no) 2023-03-07
ES2731625T3 (es) 2019-11-18
EP2327415B1 (en) 2017-10-18
ATE534400T1 (de) 2011-12-15
US7547435B2 (en) 2009-06-16
JP5451533B2 (ja) 2014-03-26
EP2327416A1 (en) 2011-06-01
US20080050356A1 (en) 2008-02-28
HK1082419A1 (en) 2006-06-09
IL202851A (en) 2015-04-30
CA2508606C (en) 2015-07-28
US7867489B2 (en) 2011-01-11
AU2003300821B2 (en) 2009-07-09
LU92273I2 (fr) 2013-10-29
US20080095753A1 (en) 2008-04-24
IL213838A0 (en) 2011-07-31
US20090074739A1 (en) 2009-03-19
AU2003300821C1 (en) 2012-03-22
BR0317033A (pt) 2005-10-25
MXPA05006038A (es) 2006-03-08
SI1581254T1 (sl) 2012-05-31
NO20052988D0 (no) 2005-06-17
CY2013033I1 (el) 2015-11-04
US20130202613A1 (en) 2013-08-08
JP2010222369A (ja) 2010-10-07
EP2327415A1 (en) 2011-06-01
EP1581254B1 (en) 2011-11-23
US9770494B2 (en) 2017-09-26
US8383105B2 (en) 2013-02-26
BRPI0310144A8 (pt) 2018-04-24
US8834869B2 (en) 2014-09-16
US20050118158A1 (en) 2005-06-02
US20130195887A1 (en) 2013-08-01
NO20121169A1 (no) 2012-10-12
IL169008A (en) 2011-08-31
US20090081187A1 (en) 2009-03-26
US8747842B2 (en) 2014-06-10
HUS1300040I1 (hu) 2013-08-15
NO20052988L (no) 2005-09-05
JP5739487B2 (ja) 2015-06-24
PT1581254E (pt) 2012-02-06
NO20121170A1 (no) 2012-10-12
GB0228409D0 (en) 2003-01-08
US20110300123A1 (en) 2011-12-08
CN100577202C (zh) 2010-01-06
US9186394B2 (en) 2015-11-17
WO2004052228A3 (en) 2004-10-07
CA2508606A1 (en) 2004-06-24
AU2003300821A1 (en) 2004-06-30
NO333837B1 (no) 2013-09-30
ES2377965T3 (es) 2012-04-03
NO343759B1 (no) 2019-06-03
ZA200505193B (en) 2007-08-29
JP5996026B2 (ja) 2016-09-21
PT2327416T (pt) 2019-07-04
CY2013033I2 (el) 2015-11-04
US20150064161A1 (en) 2015-03-05
IL202851A0 (en) 2011-07-31
LU92273I9 (no) 2019-01-15
US20110171190A1 (en) 2011-07-14

Similar Documents

Publication Publication Date Title
NO2013016I1 (no) Okriplasmin
ATE426413T1 (de) Verfahren und zusammensetzungen zur behandlung von okularer neovaskularisierung und nervenverletzungen
ATE429914T1 (de) Verwendung von makroliden zur wiederherstellung der kornealempfindungen
BR0317774A (pt) Uso de rimexolona no tratamento de olho seco
DK1515741T3 (da) Anvendelse af kollagen-hydrolysat til viskositetssænkning af en sammensætning omfattende guargummi
CY1114048T1 (el) Συνδυασμος βριμονιδινης και τιμολολης για τοπικη οφθαλμικη χρηση
AR036199A1 (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas
ATE535257T1 (de) Ophthalmologische formulierung mit methylsulfonylmethan und ciprofloxacin
WO2004069181A3 (en) Composition for the treatment of intraocular pressure
DK1263363T3 (da) Farvet viskoelastisk sammensætning
CY1106409T1 (el) Παραγωγα κινολινης
ATE550015T1 (de) Verfahren und zusammensetzung zur behandlung von rhinitis
AR031288A1 (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas
DE60317098D1 (de) Carbostyril-derivate mit selektiven serotonin-aufnahme inhibitoren, zur behandlung von gemütskrankheiten
UY28202A1 (es) Utilización de esteroides en el tratamiento de personas que sufren trastonos oculares.
MX2007010295A (es) Composiciones oftalmologicas novedosas y metodo para su uso.
Yoon et al. Recurrent herpes simplex keratitis after verteporfin photodynamic therapy for corneal neovascularization
RU2005104096A (ru) Способ лечения пролиферативной витреоретинопатии
PL430675A1 (pl) Bromokryptyna do zastosowania w leczeniu chorób oczu związanych z podwyższonym poziomem śródbłonkowego czynnika wzrostu naczyń (VEGF) oraz kompozycja farmaceutyczna zawierająca bromokryptynę
UA39527A (uk) Спосіб лікування опіку очей